References
- Afdhal N, McHutchison J, Brown R, et al. Thrombocytopenia associated with chronic liver disease. J Hepatol. 2008;48(6):1000–1007.
- Giannini EG, Greco A, Marenco S, et al. Incidence of bleeding following invasive procedures in patients with thrombocytopenia and advanced liver disease. Clin Gastroenterol Hepatol. 2010;8(10):899–902.
- Schiffer CA, Anderson KC, Bennett CL, et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19(5):1519–1538.
- McCullough J. Current issues with platelet transfusion in patients with cancer. Semin Hematol. 2000;37(2 Suppl 4):3–10.
- Perrotta PL, Snyder EL. Non-infectious complications of transfusion therapy. Blood Rev. 2001;15(2):69–83.
- Kim ES. Lusutrombopag: first global approval. Drugs. 2016;76(1):155–158.
- Miller JB, Figueroa EJ, Haug RM, et al. Thrombocytopenia in chronic liver disease and the role of thrombopoietin agonists. Gastroenterol Hepatol. 2019;15(6):326–332.
- Hidaka H, Kurosaki M, Tanaka H, et al. Lusutrombopag reduces need for platelet transfusion in patients with thrombocytopenia undergoing invasive procedures. Clin Gastroenterol Hepatol. 2019;17(6):1192–1200.
- Peck-Radosavljevic M, Simon K, Iacobellis A, et al. Lusutrombopag for the treatment of thrombocytopenia in patients with chronic liver disease undergoing invasive procedures (L-PLUS 2). Hepatology. 2019;70(4):1336–1348.
- Tateishi R, Seike M, Kudo M, et al. A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablation. J Gastroenterol. 2019;54(2):171–181.
- Sasaki R, Shiino C, Imawari M, et al. Safety and effectiveness of lusutrombopag in Japanese chronic liver disease patients with thrombocytopenia undergoing invasive procedures: interim results of a postmarketing surveillance. Hepatol Res. 2019;49(10):1169–1181.
- Mitchell O, Feldman DM, Diakow M, et al. The pathophysiology of thrombocytopenia in chronic liver disease. Hepat Med. 2016;8:39–50.
- Qamar AA, Grace ND. Abnormal hematological indices in cirrhosis. Can J Gastroenterol. 2009;23(6):441–445.
- Latorre R, Vaquero J, Rincón D, et al. Determinants of platelet count are different in patients with compensated and decompensated cirrhosis. Liver Int. 2016;36(2):232–239.
- Hirooka M, Ochi H, Hiraoka A, et al. Role of severe thrombocytopenia in preventing platelet count recovery in thrombocytopenic patients with chronic liver disease. J Gastroenterol Hepatol. 2020;35(2):299–304.
- Uojima H, Arase Y, Itokawa N, et al. Relationship between response to lusutrombopag and splenic volume. World J Gastroenterol. 2018;24(46):5271–5279.
- Dmitrienko A, Koch GG. Analysis of clinical trials using SAS: a practical guide. 2nd ed. Cary, (NC): SAS Institute Inc.; 2017.
- Goulis J, Chau TN, Jordan S, et al. Thrombopoietin concentrations are low in patients with cirrhosis and thrombocytopenia and are restored after orthotopic liver transplantation. Gut. 1999;44(5):754–758.
- Martin TG, 3rd, Somberg KA, Meng YG, et al. Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation. Ann Intern Med. 1997;127(4):285–288.
- Peck-Radosavljevic M, Zacherl J, Meng YG, et al. Is inadequate thrombopoietin production a major cause of thrombocytopenia in cirrhosis of the liver? J Hepatol. 1997;27(1):127–131.
- Aref S, Mabed M, Selim T, et al. Thrombopoietin (TPO) levels in hepatic patients with thrombocytopenia. Hematology. 2004;9(5–6):351–356.
- Schöffski P, Tacke F, Trautwein C, et al. Thrombopoietin serum levels are elevated in patients with hepatitis B/C infection compared to other causes of chronic liver disease. Liver. 2002;22(2):114–120.
- Stockelberg D, Andersson P, Björnsson E, et al. Plasma thrombopoietin levels in liver cirrhosis and kidney failure. J Intern Med. 1999;246(5):471–475.
- Vyzantiadis T, Theodoridou S, Giouleme O, et al. Serum thrombopoietin levels in thrombocytopenic patients with liver cirrhosis. Haematologica. 2002;87(8):890–891.
- Adinolfi LE, Giordano MG, Andreana A, et al. Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis. Br J Haematol. 2001;113(3):590–595.
- Brown RS, Imawari M, Izumi N, et al. Assessing the periprocedural magnitude of platelet count change in response to lusutrombopag. JHEP Rep. 2021;3(2):100228.
- Lu YF, Li XQ, Han XY, et al. Peripheral blood cell variations in cirrhotic portal hypertension patients with hypersplenism. Asian Pac J Trop Med. 2013;6(8):663–666.
- Eissa LA, Gad LS, Rabie AM, et al. Thrombopoietin level in patients with chronic liver diseases. Ann Hepatol. 2008;7(3):235–244.
- Jelkmann W. The role of the liver in the production of thrombopoietin compared with erythropoietin. Eur J Gastroenterol Hepatol. 2001;13(7):791–801.